Structured Review

Roche viral kinetics plasma hcv rna load
NKG2D expression on CD56+CD3+ lymphocytes predicts treatment responses to PEG-IFN/ ribavirin therapy. PBMCs were collected and analyzed by flow cytometry for NKG2D expression on CD56+CD3+ lymphocytes before treatment. Plasma <t>HCV-RNA</t> levels were measured regularly to monitor viral kinetics during treatment. (A, left) Correlation of decreased plasma HCV RNA (IU/ml) from week 0 to week 4 and NKG2D expression on CD56+CD3+ lymphocytes is shown. (A, right) NKG2D expression was analyzed to compare RVR (n = 8) and non-RVR (n = 22) cases. (B) NKG2D expression on CD56+CD3+ lymphocytes was analyzed to (i) compare SVR (n = 17) and non-SVR (n = 13) cases; (ii) SVR (n = 4), PR (n = 9), and NR (n = 4) in genotype 1 infection; (iii) ROC analysis to predict SVR by NKG2D expression on CD56+CD3+ lymphocytes. (C) Pre-treatment peripheral CD56+CD3+ lymphocytes were stratified into CD4+CD8-, CD8+CD4- and CD4-CD8- double negative (DN) subpopulations. NKG2D expression on corresponding subpopulations were determined. Statistics of NKG2D expression were compared between SVR (n = 17) and non-SVR (n = 13) cases, including both genotypes. Data show mean ± SD. *P
Viral Kinetics Plasma Hcv Rna Load, supplied by Roche, used in various techniques. Bioz Stars score: 88/100, based on 422 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/viral kinetics plasma hcv rna load/product/Roche
Average 88 stars, based on 422 article reviews
Price from $9.99 to $1999.99
viral kinetics plasma hcv rna load - by Bioz Stars, 2020-05
88/100 stars

Images

1) Product Images from "Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C"

Article Title: Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C

Journal: PLoS ONE

doi: 10.1371/journal.pone.0125664

NKG2D expression on CD56+CD3+ lymphocytes predicts treatment responses to PEG-IFN/ ribavirin therapy. PBMCs were collected and analyzed by flow cytometry for NKG2D expression on CD56+CD3+ lymphocytes before treatment. Plasma HCV-RNA levels were measured regularly to monitor viral kinetics during treatment. (A, left) Correlation of decreased plasma HCV RNA (IU/ml) from week 0 to week 4 and NKG2D expression on CD56+CD3+ lymphocytes is shown. (A, right) NKG2D expression was analyzed to compare RVR (n = 8) and non-RVR (n = 22) cases. (B) NKG2D expression on CD56+CD3+ lymphocytes was analyzed to (i) compare SVR (n = 17) and non-SVR (n = 13) cases; (ii) SVR (n = 4), PR (n = 9), and NR (n = 4) in genotype 1 infection; (iii) ROC analysis to predict SVR by NKG2D expression on CD56+CD3+ lymphocytes. (C) Pre-treatment peripheral CD56+CD3+ lymphocytes were stratified into CD4+CD8-, CD8+CD4- and CD4-CD8- double negative (DN) subpopulations. NKG2D expression on corresponding subpopulations were determined. Statistics of NKG2D expression were compared between SVR (n = 17) and non-SVR (n = 13) cases, including both genotypes. Data show mean ± SD. *P
Figure Legend Snippet: NKG2D expression on CD56+CD3+ lymphocytes predicts treatment responses to PEG-IFN/ ribavirin therapy. PBMCs were collected and analyzed by flow cytometry for NKG2D expression on CD56+CD3+ lymphocytes before treatment. Plasma HCV-RNA levels were measured regularly to monitor viral kinetics during treatment. (A, left) Correlation of decreased plasma HCV RNA (IU/ml) from week 0 to week 4 and NKG2D expression on CD56+CD3+ lymphocytes is shown. (A, right) NKG2D expression was analyzed to compare RVR (n = 8) and non-RVR (n = 22) cases. (B) NKG2D expression on CD56+CD3+ lymphocytes was analyzed to (i) compare SVR (n = 17) and non-SVR (n = 13) cases; (ii) SVR (n = 4), PR (n = 9), and NR (n = 4) in genotype 1 infection; (iii) ROC analysis to predict SVR by NKG2D expression on CD56+CD3+ lymphocytes. (C) Pre-treatment peripheral CD56+CD3+ lymphocytes were stratified into CD4+CD8-, CD8+CD4- and CD4-CD8- double negative (DN) subpopulations. NKG2D expression on corresponding subpopulations were determined. Statistics of NKG2D expression were compared between SVR (n = 17) and non-SVR (n = 13) cases, including both genotypes. Data show mean ± SD. *P

Techniques Used: Expressing, Flow Cytometry, Cytometry, Infection

NKG2D expression on CD56+CD3+ lymphocytes has no significant correlation to age, HCV-RNA levels or liver fibrotic degree. PBMCs were collected and analyzed by flow cytometry for expression of NKG2D on CD56+CD3+ lymphocytes. Statistics of data including age, HCV-RNA, peripheral platelet count, and serum type IV collagen 7s levels were analyzed for correlation. Please refer to supporting S1 Table for detailed values.
Figure Legend Snippet: NKG2D expression on CD56+CD3+ lymphocytes has no significant correlation to age, HCV-RNA levels or liver fibrotic degree. PBMCs were collected and analyzed by flow cytometry for expression of NKG2D on CD56+CD3+ lymphocytes. Statistics of data including age, HCV-RNA, peripheral platelet count, and serum type IV collagen 7s levels were analyzed for correlation. Please refer to supporting S1 Table for detailed values.

Techniques Used: Expressing, Flow Cytometry, Cytometry

2) Product Images from "Expanding the Host Range of Hepatitis C Virus through Viral Adaptation"

Article Title: Expanding the Host Range of Hepatitis C Virus through Viral Adaptation

Journal: mBio

doi: 10.1128/mBio.01915-16

Infection of mice with blunted innate immunity does not result in persistent infection. Mice with a fully intact innate immune system (wild-type [WT]) or lacking STAT1 were infected with 5 × 10 6 TCID 50 of Jc1 or Jc1/mCD81. HCV RNA levels (number of copies [cop] per milliliter) were measured by qRT-PCR at the indicated time points. Each symbol represents the value f or an individual animal. The dashed line shows the limit of detection (l.o.d.).
Figure Legend Snippet: Infection of mice with blunted innate immunity does not result in persistent infection. Mice with a fully intact innate immune system (wild-type [WT]) or lacking STAT1 were infected with 5 × 10 6 TCID 50 of Jc1 or Jc1/mCD81. HCV RNA levels (number of copies [cop] per milliliter) were measured by qRT-PCR at the indicated time points. Each symbol represents the value f or an individual animal. The dashed line shows the limit of detection (l.o.d.).

Techniques Used: Infection, Mouse Assay, Quantitative RT-PCR

3) Product Images from "Individualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China"

Article Title: Individualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China

Journal: International Journal of Clinical and Experimental Medicine

doi:

Virological responses in CHC patients treated with HCV RNA load at baseline Overall, The ratio of RVR, cEVR and SVR for high HCV RNA load was significantly lower than for low HCV RNA load (55.6% vs 68.2%, P =0.037; 80.2% vs 89.4%, P =0.038; 72.2% vs 86.4%,
Figure Legend Snippet: Virological responses in CHC patients treated with HCV RNA load at baseline Overall, The ratio of RVR, cEVR and SVR for high HCV RNA load was significantly lower than for low HCV RNA load (55.6% vs 68.2%, P =0.037; 80.2% vs 89.4%, P =0.038; 72.2% vs 86.4%,

Techniques Used:

4) Product Images from "Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis"

Article Title: Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis

Journal: Journal of Clinical and Experimental Hepatology

doi: 10.1016/j.jceh.2017.06.006

Distribution of IL-18 polymorphism gene. A: reveals the percentage of gene allele distribution in HCV patients. B: the percentage of C/C in responders (32 patients) compared to relapsers groups (0 patients) (35.2% versus 0%, respectively), and the percentage of A/C in relapsers (5 patients) compared to responders (59 patients) (100% versus 64.8% respectively), with no statistical significant between these groups, P = 0.16. C: PCR digestion for −607 polymorphism IL-18 gene allele: Agarose gel electrophoresis analysis of rs1946518 polymorphism in IL-18 gene. CC genotype produced only in 154 bp band and AC genotype produced 3 bands 154, 125 and 28 bp, respectively. M line represents the 50 bp molecular gene ruler DNA ladder used as a marker and 250 bp as a reference band (28 bp band not appear).
Figure Legend Snippet: Distribution of IL-18 polymorphism gene. A: reveals the percentage of gene allele distribution in HCV patients. B: the percentage of C/C in responders (32 patients) compared to relapsers groups (0 patients) (35.2% versus 0%, respectively), and the percentage of A/C in relapsers (5 patients) compared to responders (59 patients) (100% versus 64.8% respectively), with no statistical significant between these groups, P = 0.16. C: PCR digestion for −607 polymorphism IL-18 gene allele: Agarose gel electrophoresis analysis of rs1946518 polymorphism in IL-18 gene. CC genotype produced only in 154 bp band and AC genotype produced 3 bands 154, 125 and 28 bp, respectively. M line represents the 50 bp molecular gene ruler DNA ladder used as a marker and 250 bp as a reference band (28 bp band not appear).

Techniques Used: Polymerase Chain Reaction, Agarose Gel Electrophoresis, Produced, Marker

5) Product Images from "A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening"

Article Title: A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening

Journal: PLoS ONE

doi: 10.1371/journal.pone.0183530

Age- and gender-specific prevalence of HCV and HBV. ECLIA = electro-chemiluminescence immunoassay. Confirmed HCV exposure = positive for HCV antibodies with ECLIA and positive for HCV-RNA or HCV INNO-LIA immunoblot.
Figure Legend Snippet: Age- and gender-specific prevalence of HCV and HBV. ECLIA = electro-chemiluminescence immunoassay. Confirmed HCV exposure = positive for HCV antibodies with ECLIA and positive for HCV-RNA or HCV INNO-LIA immunoblot.

Techniques Used: Chemiluminescence Immunoassay

6) Product Images from "Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders"

Article Title: Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

Journal: Antimicrobial Agents and Chemotherapy

doi: 10.1128/AAC.01515-13

Individual HCV RNA levels in G1a-infected (A) and G1b-infected (B) prior null responders during 12 weeks of treatment with DNVr plus PegIFN alfa-2a–RBV, followed by 36 weeks of PegIFN alfa-2a–RBV and the study follow-up period. DNVr, ritonavir-boosted danoprevir; G, genotype; PegIFN alfa-2a–RBV; peginterferon alfa-2a (40KD) at 180 μg/week plus 1,000 mg or 1,200 mg/day ribavirin. *, patient discontinued treatment at day 14 due to an adverse event.
Figure Legend Snippet: Individual HCV RNA levels in G1a-infected (A) and G1b-infected (B) prior null responders during 12 weeks of treatment with DNVr plus PegIFN alfa-2a–RBV, followed by 36 weeks of PegIFN alfa-2a–RBV and the study follow-up period. DNVr, ritonavir-boosted danoprevir; G, genotype; PegIFN alfa-2a–RBV; peginterferon alfa-2a (40KD) at 180 μg/week plus 1,000 mg or 1,200 mg/day ribavirin. *, patient discontinued treatment at day 14 due to an adverse event.

Techniques Used: Infection

7) Product Images from "The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents Chronic Hepatitis C"

Article Title: The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents Chronic Hepatitis C

Journal: Gastroenterology

doi: 10.1053/j.gastro.2010.10.047

Mean Log 10 HCV RNA levels during the first 24 weeks of treatment by time on study (weeks) and treatment group
Figure Legend Snippet: Mean Log 10 HCV RNA levels during the first 24 weeks of treatment by time on study (weeks) and treatment group

Techniques Used:

8) Product Images from "Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection"

Article Title: Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection

Journal: Gastroenterology Research and Practice

doi: 10.1155/2016/7476231

Cumulative liver-related mortality according to the viral load of serum HCV RNA. No significant difference of cumulative liver-related mortality was seen in patients with high or low viral load ( P = 0.675).
Figure Legend Snippet: Cumulative liver-related mortality according to the viral load of serum HCV RNA. No significant difference of cumulative liver-related mortality was seen in patients with high or low viral load ( P = 0.675).

Techniques Used:

Cumulative incidence of hepatocellular carcinoma according to the viral load of serum HCV RNA. The cumulative incidence rate of HCC in patients with high viral load (log HCV RNA IU/mL > 6) was significantly higher than that in patients with low viral load (log HCV RNA IU/mL ≦ 6) ( P = 0.032).
Figure Legend Snippet: Cumulative incidence of hepatocellular carcinoma according to the viral load of serum HCV RNA. The cumulative incidence rate of HCC in patients with high viral load (log HCV RNA IU/mL > 6) was significantly higher than that in patients with low viral load (log HCV RNA IU/mL ≦ 6) ( P = 0.032).

Techniques Used:

9) Product Images from "Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5"

Article Title: Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.44.3.729-737.2006

Correlation of HCV RNA concentrations of clinical samples between the CAM and the HPS/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and
Figure Legend Snippet: Correlation of HCV RNA concentrations of clinical samples between the CAM and the HPS/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and

Techniques Used: Chick Chorioallantoic Membrane Assay

Correlation of HCV RNA concentrations of clinical samples between the CAM and the CAP/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and
Figure Legend Snippet: Correlation of HCV RNA concentrations of clinical samples between the CAM and the CAP/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and

Techniques Used: Chick Chorioallantoic Membrane Assay

Correlation of HCV RNA concentrations of clinical samples between the CAM and the bDNA assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and
Figure Legend Snippet: Correlation of HCV RNA concentrations of clinical samples between the CAM and the bDNA assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and

Techniques Used: Chick Chorioallantoic Membrane Assay

10) Product Images from "Twenty four-week peginterferon plus ribavirin after interferon-? induction for genotype 1b chronic hepatitis C"

Article Title: Twenty four-week peginterferon plus ribavirin after interferon-? induction for genotype 1b chronic hepatitis C

Journal: World Journal of Hepatology

doi: 10.4254/wjh.v2.i6.226

HCV-RNA response
Figure Legend Snippet: HCV-RNA response

Techniques Used:

The SVR rate (%, n ) by the baseline platelet count in patients whose HCV-RNA level decreased to below 3.3 Log IU/mL at the end of interferon-β treatment. Higher PLT indicates a platelet (PLT) count of ≥ 130 000/mL at the start
Figure Legend Snippet: The SVR rate (%, n ) by the baseline platelet count in patients whose HCV-RNA level decreased to below 3.3 Log IU/mL at the end of interferon-β treatment. Higher PLT indicates a platelet (PLT) count of ≥ 130 000/mL at the start

Techniques Used:

11) Product Images from "Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients ▿"

Article Title: Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients ▿

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.01753-08

Proportion of HCV RNA samples negative by CAM, ART, and CAP/CTM at each period after the beginning of treatment.
Figure Legend Snippet: Proportion of HCV RNA samples negative by CAM, ART, and CAP/CTM at each period after the beginning of treatment.

Techniques Used: Chick Chorioallantoic Membrane Assay

Very low levels of HCV RNA three patients who reached SVR. Of 26 patients who reached SVR, very low levels of HCV RNA (positive results below the limit of quantification) were detectable in 3 patients by ART or CAP/CTM at the end of treatment. The outcome of HCV RNA testing by CAM is represented as positive (+) or negative (−). Positive results of HCV RNA below the limit of quantification represent
Figure Legend Snippet: Very low levels of HCV RNA three patients who reached SVR. Of 26 patients who reached SVR, very low levels of HCV RNA (positive results below the limit of quantification) were detectable in 3 patients by ART or CAP/CTM at the end of treatment. The outcome of HCV RNA testing by CAM is represented as positive (+) or negative (−). Positive results of HCV RNA below the limit of quantification represent

Techniques Used: Chick Chorioallantoic Membrane Assay

12) Product Images from "Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial"

Article Title: Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial

Journal: Annals of internal medicine

doi: 10.7326/M17-2871

Pre- and Post-transplant HCV RNA Among HCV-uninfected Recipients of HCV+ Donor KT HCV plasma RNA log 10 IU/mL pre-transplant, during DAA treatment on post-operative day 1, post transplant weeks 1, 2, 4, 8 and 12 and after DAA treatment on follow-up weeks 4, 8, and 12. Lower limit of quantification is 15 IU/mL.
Figure Legend Snippet: Pre- and Post-transplant HCV RNA Among HCV-uninfected Recipients of HCV+ Donor KT HCV plasma RNA log 10 IU/mL pre-transplant, during DAA treatment on post-operative day 1, post transplant weeks 1, 2, 4, 8 and 12 and after DAA treatment on follow-up weeks 4, 8, and 12. Lower limit of quantification is 15 IU/mL.

Techniques Used:

13) Product Images from "Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3"

Article Title: Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3

Journal: PLoS ONE

doi: 10.1371/journal.pone.0029370

Impact of IL28B ( rs12979860 ) on baseline viral load and decline in mean HCV RNA day 0–3 among HCV genotype 2 and 3 infected patients. Box plots displaying the 10 th , 25 th , 50 th , 75 th , and 90 th percentiles, and p-values obtained using Kruskal-Wallis test.
Figure Legend Snippet: Impact of IL28B ( rs12979860 ) on baseline viral load and decline in mean HCV RNA day 0–3 among HCV genotype 2 and 3 infected patients. Box plots displaying the 10 th , 25 th , 50 th , 75 th , and 90 th percentiles, and p-values obtained using Kruskal-Wallis test.

Techniques Used: Infection

14) Product Images from "Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients"

Article Title: Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients

Journal: European Journal of Gastroenterology & Hepatology

doi: 10.1097/MEG.0000000000001316

Long-term FU with liver elasticity measurement using Fibroscan and testings of HCV-RNA with a highly sensitive method in patients with a sustained virological response. The values of two patients with positive HCV-RNA at FU, indicative of occult infection, are shown with filled circles. EOT, end of treatment; FU, follow-up; HCV, hepatitis C virus.
Figure Legend Snippet: Long-term FU with liver elasticity measurement using Fibroscan and testings of HCV-RNA with a highly sensitive method in patients with a sustained virological response. The values of two patients with positive HCV-RNA at FU, indicative of occult infection, are shown with filled circles. EOT, end of treatment; FU, follow-up; HCV, hepatitis C virus.

Techniques Used: Infection

15) Product Images from "Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients"

Article Title: Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients

Journal: European Journal of Gastroenterology & Hepatology

doi: 10.1097/MEG.0000000000001316

Long-term FU with liver elasticity measurement using Fibroscan and testings of HCV-RNA with a highly sensitive method in patients with a sustained virological response. The values of two patients with positive HCV-RNA at FU, indicative of occult infection, are shown with filled circles. EOT, end of treatment; FU, follow-up; HCV, hepatitis C virus.
Figure Legend Snippet: Long-term FU with liver elasticity measurement using Fibroscan and testings of HCV-RNA with a highly sensitive method in patients with a sustained virological response. The values of two patients with positive HCV-RNA at FU, indicative of occult infection, are shown with filled circles. EOT, end of treatment; FU, follow-up; HCV, hepatitis C virus.

Techniques Used: Infection

16) Product Images from "Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets"

Article Title: Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets

Journal: Scientific Reports

doi: 10.1038/srep31777

Effect of quercetin on HCV life cycle in PHH. PHH were infected with JFH1 (MOI of 2.5) for 6 h and then treated with 50 μM quercetin (JFH1 + Q50 μM), or DMSO as carrier control, for 24 h ( a ) or 72 h ( b,c ). ( a ) Cells were lysed for quantification of negative-strand HCV RNA. ( b,c ) Culture supernatant were collected for determination of extracellular HCV RNA level and infectivity titer, respectively. Results are expressed as percentage of carrier control. Data are presented as the mean values ± SD obtained from two to three independent experiments.
Figure Legend Snippet: Effect of quercetin on HCV life cycle in PHH. PHH were infected with JFH1 (MOI of 2.5) for 6 h and then treated with 50 μM quercetin (JFH1 + Q50 μM), or DMSO as carrier control, for 24 h ( a ) or 72 h ( b,c ). ( a ) Cells were lysed for quantification of negative-strand HCV RNA. ( b,c ) Culture supernatant were collected for determination of extracellular HCV RNA level and infectivity titer, respectively. Results are expressed as percentage of carrier control. Data are presented as the mean values ± SD obtained from two to three independent experiments.

Techniques Used: Infection

Effect of quercetin on HCV viral life cycle in Huh-7.5.1 cells. Huh-7.5.1 cells were infected with JFH1 for 6 h and then treated with 50 μM of quercetin (JFH1 + Q50 μM), or DMSO as carrier control, for 24 h ( a ) or 72 h ( b,d ). ( a,b ) Cells were lysed for quantification of negative-strand HCV RNA. ( c,d ) Culture supernatant were collected for determination of extracellular HCV RNA level and infectivity titer. Results are expressed as percentage of vehicle control. Data are presented as the mean values ± SD obtained from three independent experiments.
Figure Legend Snippet: Effect of quercetin on HCV viral life cycle in Huh-7.5.1 cells. Huh-7.5.1 cells were infected with JFH1 for 6 h and then treated with 50 μM of quercetin (JFH1 + Q50 μM), or DMSO as carrier control, for 24 h ( a ) or 72 h ( b,d ). ( a,b ) Cells were lysed for quantification of negative-strand HCV RNA. ( c,d ) Culture supernatant were collected for determination of extracellular HCV RNA level and infectivity titer. Results are expressed as percentage of vehicle control. Data are presented as the mean values ± SD obtained from three independent experiments.

Techniques Used: Infection

17) Product Images from "Specific Acquisition of Functional CD59 but Not CD46 or CD55 by Hepatitis C Virus"

Article Title: Specific Acquisition of Functional CD59 but Not CD46 or CD55 by Hepatitis C Virus

Journal: PLoS ONE

doi: 10.1371/journal.pone.0045770

Impact of CD59 knock-down of the HCV replication cycle and virolysis. ( A ) Huh 7.5 cells were reverse-transfected with two different concentrations of siRNA against CD59 and then incubated for 72 h. Western blot analysis were performed against HCV NS3, β-actin and CD59. ( B ) The 25 nM siRNA-treated and mock treated viral supernatants were incubated with 25% normal human serum (NHS) as source of active complement or in combination with anti-env (AP33) and 25% heat-inactivated normal human serum (h.i.NHS) as control. ( C ) At 48 h post infection, the different siRNA CD59-treated cells were lysed with luciferase lysis buffer and analyzed for RNA replication efficiency by determination of luciferase acitivity. ( D ) The supernatants of transfected cells were collected and used to infect naive Huh 7.5 cells. At 48 h post infection, the cells were lysed and analysed with renilla luciferase assay for virus infectivity level.
Figure Legend Snippet: Impact of CD59 knock-down of the HCV replication cycle and virolysis. ( A ) Huh 7.5 cells were reverse-transfected with two different concentrations of siRNA against CD59 and then incubated for 72 h. Western blot analysis were performed against HCV NS3, β-actin and CD59. ( B ) The 25 nM siRNA-treated and mock treated viral supernatants were incubated with 25% normal human serum (NHS) as source of active complement or in combination with anti-env (AP33) and 25% heat-inactivated normal human serum (h.i.NHS) as control. ( C ) At 48 h post infection, the different siRNA CD59-treated cells were lysed with luciferase lysis buffer and analyzed for RNA replication efficiency by determination of luciferase acitivity. ( D ) The supernatants of transfected cells were collected and used to infect naive Huh 7.5 cells. At 48 h post infection, the cells were lysed and analysed with renilla luciferase assay for virus infectivity level.

Techniques Used: Transfection, Incubation, Western Blot, Infection, Luciferase, Lysis

Detection of membrane bound complement regulators CD59, CD55 and CD46 associated on patient-derived HCV isolates. Purified HCV particles isolated from HCV infected patients were subjected to virus capture assay using 96 well plate coated with either 5 µg anti-human CD59, anti-human CD55 or anti-human CD46 . RNA isolated from the captured wells was analyzed using Roche T aq Man assay. Figures represent the individual results from 9 different patient serum samples. Significance was calculated using unpaired t -test.
Figure Legend Snippet: Detection of membrane bound complement regulators CD59, CD55 and CD46 associated on patient-derived HCV isolates. Purified HCV particles isolated from HCV infected patients were subjected to virus capture assay using 96 well plate coated with either 5 µg anti-human CD59, anti-human CD55 or anti-human CD46 . RNA isolated from the captured wells was analyzed using Roche T aq Man assay. Figures represent the individual results from 9 different patient serum samples. Significance was calculated using unpaired t -test.

Techniques Used: Derivative Assay, Purification, Isolation, Infection

Detection of IgG and complement fragments associated with patient-derived HCV isolates. Purified HCV particles isolated from HCV infected patients were subjected to virus capture assay using 96 well plates coated with 5 µg anti-human IgG or isotype antibody ( A ) and anti-human C3 or isotype antibody ( B ) .RNA isolated from the captured wells was analyzed using Roche T aq Man assay. Figures represent the individual results from 9 different patient serum samples. Significance was calculated using unpaired t -test.
Figure Legend Snippet: Detection of IgG and complement fragments associated with patient-derived HCV isolates. Purified HCV particles isolated from HCV infected patients were subjected to virus capture assay using 96 well plates coated with 5 µg anti-human IgG or isotype antibody ( A ) and anti-human C3 or isotype antibody ( B ) .RNA isolated from the captured wells was analyzed using Roche T aq Man assay. Figures represent the individual results from 9 different patient serum samples. Significance was calculated using unpaired t -test.

Techniques Used: Derivative Assay, Purification, Isolation, Infection

18) Product Images from "Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1"

Article Title: Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1

Journal: PLoS ONE

doi: 10.1371/journal.pone.0163884

The virological response during and after treatment according to Y93 and L31 baseline status by direct sequencing. (A) Y93. (B) L31. One patient for whom Y93 and L31 results were not obtained was excluded. Five patients who were lost to follow-up and three patients who died were not included. The HCV RNA negative rate was analyzed using Fisher’s exact test.
Figure Legend Snippet: The virological response during and after treatment according to Y93 and L31 baseline status by direct sequencing. (A) Y93. (B) L31. One patient for whom Y93 and L31 results were not obtained was excluded. Five patients who were lost to follow-up and three patients who died were not included. The HCV RNA negative rate was analyzed using Fisher’s exact test.

Techniques Used: Sequencing

19) Product Images from "Impact of Obesity on the Bioavailability of Peginterferon-?2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3"

Article Title: Impact of Obesity on the Bioavailability of Peginterferon-?2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3

Journal: PLoS ONE

doi: 10.1371/journal.pone.0037521

Impact of interferon concentration on first phase decline in HCV RNA. Correlation between the plasma concentration of peginterferon (pg/mL) treatment day 3 and decline in HCV RNA (log 10 IU/mL) between baseline and treatment day 3 of combination therapy evaluated by use of Spearman's rank correlation coefficient r s test.
Figure Legend Snippet: Impact of interferon concentration on first phase decline in HCV RNA. Correlation between the plasma concentration of peginterferon (pg/mL) treatment day 3 and decline in HCV RNA (log 10 IU/mL) between baseline and treatment day 3 of combination therapy evaluated by use of Spearman's rank correlation coefficient r s test.

Techniques Used: Concentration Assay

20) Product Images from "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection"

Article Title: Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection

Journal: World Journal of Hepatology

doi: 10.4254/wjh.v9.i4.217

Overall study design. Group A refers to treatment naïve participants while Group B refers to treatment experienced participants. PEG/WBR treatment is pegylated-interferon alfa 2b (PEG-IFN) and weight-based ribavirin (WBR). 1 Cirrhotic participants received 44 wk of triple therapy. SVR12: HCV RNA
Figure Legend Snippet: Overall study design. Group A refers to treatment naïve participants while Group B refers to treatment experienced participants. PEG/WBR treatment is pegylated-interferon alfa 2b (PEG-IFN) and weight-based ribavirin (WBR). 1 Cirrhotic participants received 44 wk of triple therapy. SVR12: HCV RNA

Techniques Used:

21) Product Images from "Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection"

Article Title: Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection

Journal: Gut and Liver

doi: 10.5009/gnl.2014.8.1.70

A suggested algorithm for the expected probability of sustained virologic response (SVR) according to the presence of the interleukin-28B ( IL28B ) polymorphism (rs12979860), platelet count, and hepatitis C virus (HCV) RNA levels in Korean patients infected with HCV genotype 1. Among the 70 total patients included in this algorithm, all five patients exhibiting the IL28B non-CC type and a low platelet count (7%) did not achieve SVR. However, all 14 patients exhibiting the IL28B CC type, a normal platelet count, and low HCV RNA levels (20%) achieved SVR. Between these extremes, SVR rates ranged from 17% to 68%.
Figure Legend Snippet: A suggested algorithm for the expected probability of sustained virologic response (SVR) according to the presence of the interleukin-28B ( IL28B ) polymorphism (rs12979860), platelet count, and hepatitis C virus (HCV) RNA levels in Korean patients infected with HCV genotype 1. Among the 70 total patients included in this algorithm, all five patients exhibiting the IL28B non-CC type and a low platelet count (7%) did not achieve SVR. However, all 14 patients exhibiting the IL28B CC type, a normal platelet count, and low HCV RNA levels (20%) achieved SVR. Between these extremes, SVR rates ranged from 17% to 68%.

Techniques Used: Infection

22) Product Images from "Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5"

Article Title: Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.44.3.729-737.2006

Correlation of HCV RNA concentrations of clinical samples between the CAM and the HPS/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and
Figure Legend Snippet: Correlation of HCV RNA concentrations of clinical samples between the CAM and the HPS/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and

Techniques Used: Chick Chorioallantoic Membrane Assay

Correlation of HCV RNA concentrations of clinical samples between the CAM and the CAP/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and
Figure Legend Snippet: Correlation of HCV RNA concentrations of clinical samples between the CAM and the CAP/CTM assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and

Techniques Used: Chick Chorioallantoic Membrane Assay

Correlation of HCV RNA concentrations of clinical samples between the CAM and the bDNA assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and
Figure Legend Snippet: Correlation of HCV RNA concentrations of clinical samples between the CAM and the bDNA assays. Results are shown separately for HCV genotype 1a/b, 2a/c, 2b, 3a, 4, and 5 samples. In addition to the single HCV RNA concentrations, the identity line and

Techniques Used: Chick Chorioallantoic Membrane Assay

23) Product Images from "Twenty four-week peginterferon plus ribavirin after interferon-? induction for genotype 1b chronic hepatitis C"

Article Title: Twenty four-week peginterferon plus ribavirin after interferon-? induction for genotype 1b chronic hepatitis C

Journal: World Journal of Hepatology

doi: 10.4254/wjh.v2.i6.226

HCV-RNA response
Figure Legend Snippet: HCV-RNA response

Techniques Used:

The SVR rate (%, n ) by the baseline platelet count in patients whose HCV-RNA level decreased to below 3.3 Log IU/mL at the end of interferon-β treatment. Higher PLT indicates a platelet (PLT) count of ≥ 130 000/mL at the start
Figure Legend Snippet: The SVR rate (%, n ) by the baseline platelet count in patients whose HCV-RNA level decreased to below 3.3 Log IU/mL at the end of interferon-β treatment. Higher PLT indicates a platelet (PLT) count of ≥ 130 000/mL at the start

Techniques Used:

24) Product Images from "The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1"

Article Title: The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1

Journal: Internal Medicine

doi: 10.2169/internalmedicine.0810-18

The virological responses to PTV/OBV/r treatment. (A) The percentages of patients in whom HCV RNA was undetectable during and after treatment. (B) The SVR rate according to the patient characteristics.
Figure Legend Snippet: The virological responses to PTV/OBV/r treatment. (A) The percentages of patients in whom HCV RNA was undetectable during and after treatment. (B) The SVR rate according to the patient characteristics.

Techniques Used:

25) Product Images from "Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9"

Article Title: Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9

Journal: EBioMedicine

doi: 10.1016/j.ebiom.2017.08.020

Cohort overview and study design for miRNA analysis. a) Plasma samples were collected from a cohort of 94 patients chronically infected with HCV. All patients were treated with interferon-based antiviral therapy that included pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) with/without an oral HCV protease inhibitor [boceprevir (BOC)/telaprevir (TPV)] for 24–48 weeks [Treatment Week (TW) 24-TW48]. Plasma samples were collected before [Week 0 (W0)], during treatment (TW4-TW24/TW48), and after treatment [Follow-Up Week: (FUW)] at the indicated time points (FUW12/FUW24). b) Circulating levels of plasma miR-122, miR-24, and miR-223 were quantified by quantitative real-time PCR after total RNA isolation. MicroRNA levels were normalized to a non-human spike-in control [ Caenorhabditis elegans miR-39 (cel-miR-39)]. Clinical relevance of circulating levels of plasma miR-122, miR-24, and miR-223 in CHC infection and their impacts on treatment outcome were evaluated using various statistical models (see Materials and methods ).
Figure Legend Snippet: Cohort overview and study design for miRNA analysis. a) Plasma samples were collected from a cohort of 94 patients chronically infected with HCV. All patients were treated with interferon-based antiviral therapy that included pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV) with/without an oral HCV protease inhibitor [boceprevir (BOC)/telaprevir (TPV)] for 24–48 weeks [Treatment Week (TW) 24-TW48]. Plasma samples were collected before [Week 0 (W0)], during treatment (TW4-TW24/TW48), and after treatment [Follow-Up Week: (FUW)] at the indicated time points (FUW12/FUW24). b) Circulating levels of plasma miR-122, miR-24, and miR-223 were quantified by quantitative real-time PCR after total RNA isolation. MicroRNA levels were normalized to a non-human spike-in control [ Caenorhabditis elegans miR-39 (cel-miR-39)]. Clinical relevance of circulating levels of plasma miR-122, miR-24, and miR-223 in CHC infection and their impacts on treatment outcome were evaluated using various statistical models (see Materials and methods ).

Techniques Used: Infection, Protease Inhibitor, Real-time Polymerase Chain Reaction, Isolation

26) Product Images from "Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects"

Article Title: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

Journal: PLoS ONE

doi: 10.1371/journal.pone.0204974

Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.
Figure Legend Snippet: Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.

Techniques Used: Infection, Standard Deviation

Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (
Figure Legend Snippet: Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (

Techniques Used:

27) Product Images from "Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment"

Article Title: Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment

Journal: BMC Gastroenterology

doi: 10.1186/1471-230X-10-38

The distribution of timing of HCV RNA undetectable after the initiation of treatment at weeks 2, 4, 8, and 12 in comparison with TaqMan and qualitative Amplicor assays . SVR, sustained virological response.
Figure Legend Snippet: The distribution of timing of HCV RNA undetectable after the initiation of treatment at weeks 2, 4, 8, and 12 in comparison with TaqMan and qualitative Amplicor assays . SVR, sustained virological response.

Techniques Used:

28) Product Images from "Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial"

Article Title: Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

Journal: Infectious Diseases and Therapy

doi: 10.1007/s40121-016-0110-5

Virological response over time. Virological response is defined as undetectable HCV RNA (Roche COBAS TaqMan ® 2.0 HCV Test). EOT end of treatment, HCV hepatitis C virus; RNA ribonucleic acid
Figure Legend Snippet: Virological response over time. Virological response is defined as undetectable HCV RNA (Roche COBAS TaqMan ® 2.0 HCV Test). EOT end of treatment, HCV hepatitis C virus; RNA ribonucleic acid

Techniques Used:

Patient disposition and reason for premature withdrawal from treatment or follow-up. Asterisk early response is defined as patients with undetectable HCV RNA at week 8, HCV RNA
Figure Legend Snippet: Patient disposition and reason for premature withdrawal from treatment or follow-up. Asterisk early response is defined as patients with undetectable HCV RNA at week 8, HCV RNA

Techniques Used:

29) Product Images from "Genotypic and Phenotypic Analyses of Hepatitis C Virus from Patients Treated with JTK-853 in a Three-Day Monotherapy"

Article Title: Genotypic and Phenotypic Analyses of Hepatitis C Virus from Patients Treated with JTK-853 in a Three-Day Monotherapy

Journal: Antimicrobial Agents and Chemotherapy

doi: 10.1128/AAC.01432-12

Correlations between the viral reduction in JTK-853-treated HCV-infected patients and the JTK-853 susceptibility in their NS5B -harboring replicon at the BL (A) and EOT (B). The x axis represents the EC 50 , and the y axis represents the change in HCV RNA
Figure Legend Snippet: Correlations between the viral reduction in JTK-853-treated HCV-infected patients and the JTK-853 susceptibility in their NS5B -harboring replicon at the BL (A) and EOT (B). The x axis represents the EC 50 , and the y axis represents the change in HCV RNA

Techniques Used: Infection

30) Product Images from "Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0"

Article Title: Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0

Journal: Journal of Clinical Microbiology

doi: 10.1128/JCM.02102-13

Alignment of HCV 5′-untranslated sequences for two patients with HCV genotype 2a, in whom HCV RNA was undetectable by the CAP/CTM HCV v1.0 assay, against the sequence of a reference HCV genotype 2a strain (JFH-1). Nucleotide substitutions were
Figure Legend Snippet: Alignment of HCV 5′-untranslated sequences for two patients with HCV genotype 2a, in whom HCV RNA was undetectable by the CAP/CTM HCV v1.0 assay, against the sequence of a reference HCV genotype 2a strain (JFH-1). Nucleotide substitutions were

Techniques Used: Sequencing

31) Product Images from "Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects"

Article Title: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

Journal: PLoS ONE

doi: 10.1371/journal.pone.0204974

Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (
Figure Legend Snippet: Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (

Techniques Used:

Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.
Figure Legend Snippet: Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.

Techniques Used: Infection, Standard Deviation

32) Product Images from "Social networks and HCV viremia among anti-HCV positive rural drug users"

Article Title: Social networks and HCV viremia among anti-HCV positive rural drug users

Journal: Epidemiology and infection

doi: 10.1017/S0950268812000696

Multivariable correlates to HCV RNA status
Figure Legend Snippet: Multivariable correlates to HCV RNA status

Techniques Used:

HCV RNA status of randomly selected sample of anti-HCV positive drug users in a drug risk network (n=222)
Figure Legend Snippet: HCV RNA status of randomly selected sample of anti-HCV positive drug users in a drug risk network (n=222)

Techniques Used:

33) Product Images from "Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia"

Article Title: Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia

Journal: World Journal of Hepatology

doi: 10.4254/wjh.v8.i6.331

Analysis of sustained virologic response, end of treatment response, and relapse rate. If a patient had missing data at and after the FW24 window and had undetectable HCV RNA at FW12, the patient was considered a sustained virologic responder. The P value
Figure Legend Snippet: Analysis of sustained virologic response, end of treatment response, and relapse rate. If a patient had missing data at and after the FW24 window and had undetectable HCV RNA at FW12, the patient was considered a sustained virologic responder. The P value

Techniques Used:

34) Product Images from "Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus"

Article Title: Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus

Journal: Journal of Virology

doi: 10.1128/JVI.00404-16

Effect of B5 on other steps of the HCV life cycle. (A and B) Effect of B5 on HCV replication. JFH1 RNA was electroporated into Huh-7 cells, and at 4 h postelectroporation, cells were treated or not with B5 (A) or boceprevir (BCP) (B). HCV replication
Figure Legend Snippet: Effect of B5 on other steps of the HCV life cycle. (A and B) Effect of B5 on HCV replication. JFH1 RNA was electroporated into Huh-7 cells, and at 4 h postelectroporation, cells were treated or not with B5 (A) or boceprevir (BCP) (B). HCV replication

Techniques Used:

35) Product Images from "Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment"

Article Title: Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment

Journal: BMC Gastroenterology

doi: 10.1186/1471-230X-10-38

The distribution of timing of HCV RNA undetectable after the initiation of treatment at weeks 2, 4, 8, and 12 in comparison with TaqMan and qualitative Amplicor assays . SVR, sustained virological response.
Figure Legend Snippet: The distribution of timing of HCV RNA undetectable after the initiation of treatment at weeks 2, 4, 8, and 12 in comparison with TaqMan and qualitative Amplicor assays . SVR, sustained virological response.

Techniques Used:

36) Product Images from "Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods"

Article Title: Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods

Journal: PLoS ONE

doi: 10.1371/journal.pone.0187755

Frequency of negative results for HCV-RNA (blue columns) and HCV-Ag (red columns) during on-treatment monitoring and follow-up of 96 patients treated with DAAs for chronic HCV-infection.
Figure Legend Snippet: Frequency of negative results for HCV-RNA (blue columns) and HCV-Ag (red columns) during on-treatment monitoring and follow-up of 96 patients treated with DAAs for chronic HCV-infection.

Techniques Used: Infection

Receiver-operating characteristics (ROC) curves for HCV-RNA (3a) and HCV-Ag (3b) after 2, 4 and 8 weeks after starting treatment with DAAs. The horizontal axis reports the dates of blood draws (month, day) from June 2015 to April 2016 after the start of treatment.
Figure Legend Snippet: Receiver-operating characteristics (ROC) curves for HCV-RNA (3a) and HCV-Ag (3b) after 2, 4 and 8 weeks after starting treatment with DAAs. The horizontal axis reports the dates of blood draws (month, day) from June 2015 to April 2016 after the start of treatment.

Techniques Used:

Decrease (logarithmic mean values) from baseline levels of HCV-RNA and HCV-Ag during treatment; SVR = sustained viral response; RR = response with relapse; W2, W4, W8 = weeks 2, 4 and 8 after the start of treatment; * = p
Figure Legend Snippet: Decrease (logarithmic mean values) from baseline levels of HCV-RNA and HCV-Ag during treatment; SVR = sustained viral response; RR = response with relapse; W2, W4, W8 = weeks 2, 4 and 8 after the start of treatment; * = p

Techniques Used:

Monitoring profiles for HCV-RNA and HCV-Ag of a representative patient with sustained viral response after 24 weeks of treatment with Sofosbuvir + Ribavirin (2a) and of a patient with relapse after 24 weeks of treatment with Sofosbuvir + Simeprevir + Ribavirin (2b). The horizontal axis reports the dates of blood draws (month, day) from June 2015 to April 2016 after the start of treatment.
Figure Legend Snippet: Monitoring profiles for HCV-RNA and HCV-Ag of a representative patient with sustained viral response after 24 weeks of treatment with Sofosbuvir + Ribavirin (2a) and of a patient with relapse after 24 weeks of treatment with Sofosbuvir + Simeprevir + Ribavirin (2b). The horizontal axis reports the dates of blood draws (month, day) from June 2015 to April 2016 after the start of treatment.

Techniques Used:

37) Product Images from "Enhanced Activation of Memory, but Not Na?ve, B Cells in Chronic Hepatitis C Virus-Infected Patients with Cryoglobulinemia and Advanced Liver Fibrosis"

Article Title: Enhanced Activation of Memory, but Not Na?ve, B Cells in Chronic Hepatitis C Virus-Infected Patients with Cryoglobulinemia and Advanced Liver Fibrosis

Journal: PLoS ONE

doi: 10.1371/journal.pone.0068308

PBMC and B cell quantification and clinical characteristics of cryoglobulin positive versus cryoglobulin negative HCV patients. ( A–B ) PBMCs were freshly isolated and analyzed by flow cytometry as in Figure 2 except that this analysis compares cryoglobulin+ (n = 20, cryo+) and cryoglobulin- (n = 34, cryo-) HCV patients. ( A ) The total percent of CD19+ B cells within the lymphocyte gate and number of B cells per ml of blood based on our isolations. ( B ) The percent of memory (CD19+CD27+) and naïve (CD19+CD27−) and number of each subset per ml of blood. ( C ) The number of total PBMCs isolated per ml of blood. ( D ) The alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) levels were measured in the serum in units/L (U/L) for 54 (ALT) or 48 (GGT) HCV patients. ( E ) Serum HCV RNA titers were quantified by qRT-PCR as described in the Materials and Methods for all 54 HCV patients. Horizontal lines on graphs represent mean +/− SEM (A-B, percentages, C) or median (A–B numbers, D, E) values. *, P
Figure Legend Snippet: PBMC and B cell quantification and clinical characteristics of cryoglobulin positive versus cryoglobulin negative HCV patients. ( A–B ) PBMCs were freshly isolated and analyzed by flow cytometry as in Figure 2 except that this analysis compares cryoglobulin+ (n = 20, cryo+) and cryoglobulin- (n = 34, cryo-) HCV patients. ( A ) The total percent of CD19+ B cells within the lymphocyte gate and number of B cells per ml of blood based on our isolations. ( B ) The percent of memory (CD19+CD27+) and naïve (CD19+CD27−) and number of each subset per ml of blood. ( C ) The number of total PBMCs isolated per ml of blood. ( D ) The alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) levels were measured in the serum in units/L (U/L) for 54 (ALT) or 48 (GGT) HCV patients. ( E ) Serum HCV RNA titers were quantified by qRT-PCR as described in the Materials and Methods for all 54 HCV patients. Horizontal lines on graphs represent mean +/− SEM (A-B, percentages, C) or median (A–B numbers, D, E) values. *, P

Techniques Used: Isolation, Flow Cytometry, Cytometry, Quantitative RT-PCR

38) Product Images from "Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy"

Article Title: Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

Journal: PLoS ONE

doi: 10.1371/journal.pone.0125080

Proportion of patients who presented undetectable HCV RNA at the different treatment weeks (TW). (A) Proportion of patients with undetectable HCV RNA during therapy including peg-IFN plus RBV in combination with BOC. (B) Proportion of patients with undetectable HCV RNA during therapy including peg-IFN plus RBV in combination with TVR. Grey bars: Intention-to-treat analysis; black bars: on-treatment analysis. *TW8 data was available in 44 patients receiving BOC and 43 patients receiving TVR.
Figure Legend Snippet: Proportion of patients who presented undetectable HCV RNA at the different treatment weeks (TW). (A) Proportion of patients with undetectable HCV RNA during therapy including peg-IFN plus RBV in combination with BOC. (B) Proportion of patients with undetectable HCV RNA during therapy including peg-IFN plus RBV in combination with TVR. Grey bars: Intention-to-treat analysis; black bars: on-treatment analysis. *TW8 data was available in 44 patients receiving BOC and 43 patients receiving TVR.

Techniques Used:

39) Product Images from "Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C"

Article Title: Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C

Journal: PLoS ONE

doi: 10.1371/journal.pone.0195632

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 144 patients with a SVR. Boxes represent the interquartile range of the data. The line across the boxes indicates the median value. Hash marks depict the nearest value within 1.5 times the interquartile range. Open circles indicate outliers. PT: post-treatment. ***, P
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 144 patients with a SVR. Boxes represent the interquartile range of the data. The line across the boxes indicates the median value. Hash marks depict the nearest value within 1.5 times the interquartile range. Open circles indicate outliers. PT: post-treatment. ***, P

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 48 patients with ALT
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 48 patients with ALT

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 64 male patients with a SVR. PT: post-treatment. **, P
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 64 male patients with a SVR. PT: post-treatment. **, P

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 6 male patients without a SVR. PT: post-treatment. *, P
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 6 male patients without a SVR. PT: post-treatment. *, P

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 15 patients without a SVR. PT: post-treatment. *, P
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 15 patients without a SVR. PT: post-treatment. *, P

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 80 female patients with a SVR. PT: post-treatment. **, P
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 80 female patients with a SVR. PT: post-treatment. **, P

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 9 female patients without a SVR. PT: post-treatment. *, P
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 9 female patients without a SVR. PT: post-treatment. *, P

Techniques Used:

Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 6 patients with ALT
Figure Legend Snippet: Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 6 patients with ALT

Techniques Used:

40) Product Images from "High Programmed Death-1 levels on HCV specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection 1"

Article Title: High Programmed Death-1 levels on HCV specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection 1

Journal:

doi:

PD-1 expression on HCV specific T cells stratified by HCV RNA level during early and late infection
Figure Legend Snippet: PD-1 expression on HCV specific T cells stratified by HCV RNA level during early and late infection

Techniques Used: Expressing, Infection

Related Articles

Synthesized:

Article Title: Chronic hypoxia‐induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin‐B1, et al. Chronic hypoxia‐induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin‐B1
Article Snippet: .. 2.5 Real‐time quantitative RT‐PCR First‐strand cDNA was synthesized from the total RNA using ThermoScript RT‐PCR System (Roche, Indianapolis, IN, USA). .. PCR was performed on a LightCycler system (Roche) using LightCycler FastStart DNA Master SYBR Green I reaction mix (Roche) and QuantiTect Primer Assays (QIAGEN, Hilden, Germany).

Isolation:

Article Title: Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation
Article Snippet: .. Reverse transcription quantitative PCR (RT-qPCR) Total RNA was isolated from two million cells by SV total RNA isolation kit (Promega). cDNA was prepared by annealing 500 ng RNA with oligo dT as per the manufacturer’s instructions (Transcriptor High Fidelity cDNA Synthesis kit, Roche). ..

Quantitative RT-PCR:

Article Title: Chronic hypoxia‐induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin‐B1, et al. Chronic hypoxia‐induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin‐B1
Article Snippet: .. 2.5 Real‐time quantitative RT‐PCR First‐strand cDNA was synthesized from the total RNA using ThermoScript RT‐PCR System (Roche, Indianapolis, IN, USA). .. PCR was performed on a LightCycler system (Roche) using LightCycler FastStart DNA Master SYBR Green I reaction mix (Roche) and QuantiTect Primer Assays (QIAGEN, Hilden, Germany).

Article Title: Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation
Article Snippet: .. Reverse transcription quantitative PCR (RT-qPCR) Total RNA was isolated from two million cells by SV total RNA isolation kit (Promega). cDNA was prepared by annealing 500 ng RNA with oligo dT as per the manufacturer’s instructions (Transcriptor High Fidelity cDNA Synthesis kit, Roche). ..

Sampling:

Article Title: Interpretation of Positive TMA Test Results from PCR-Negative Samples Obtained after Treatment of Chronic Hepatitis C
Article Snippet: .. Alternatively, these samples might have contained extremely low levels of HCV RNA ( < 5 IU/mL), resulting in sampling variability with each test, as would be expected to occur near the limit of detection. .. To evaluate the reproducibility of the TMA test, we first selected 30 serum samples randomly from patients with detectable HCV RNA by the Roche COBAS Amplicor (PCR) test (LLOD, 100 IU/mL) but undetectable by the quantitative Monitor test (LLOD, 600 IU/mL) for re-testing with the TMA assay.

Real-time Polymerase Chain Reaction:

Article Title: Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation
Article Snippet: .. Reverse transcription quantitative PCR (RT-qPCR) Total RNA was isolated from two million cells by SV total RNA isolation kit (Promega). cDNA was prepared by annealing 500 ng RNA with oligo dT as per the manufacturer’s instructions (Transcriptor High Fidelity cDNA Synthesis kit, Roche). ..

Reverse Transcription Polymerase Chain Reaction:

Article Title: Chronic hypoxia‐induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin‐B1, et al. Chronic hypoxia‐induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin‐B1
Article Snippet: .. 2.5 Real‐time quantitative RT‐PCR First‐strand cDNA was synthesized from the total RNA using ThermoScript RT‐PCR System (Roche, Indianapolis, IN, USA). .. PCR was performed on a LightCycler system (Roche) using LightCycler FastStart DNA Master SYBR Green I reaction mix (Roche) and QuantiTect Primer Assays (QIAGEN, Hilden, Germany).

Activity Assay:

Article Title: Interpretation of Positive TMA Test Results from PCR-Negative Samples Obtained after Treatment of Chronic Hepatitis C
Article Snippet: .. Consistent with their achieving an SVR, these patients had a prompt drop in HCV RNA on therapy, were repeatedly PCR-negative from week 20 through week 72, and had a significant decline in ALT activity from baseline to week 72. .. Most importantly, all 9 remained HCV RNA-negative by both PCR and TMA after week 72.

Infection:

Article Title: Interpretation of Positive TMA Test Results from PCR-Negative Samples Obtained after Treatment of Chronic Hepatitis C
Article Snippet: .. Conversely, if discordant TMA results were due to low HCV RNA copy numbers close to the limit of detection, then discordant results might be expected to reflect a transition from HCV RNA consistently detectable to HCV RNA consistently undetectable by TMA as HCV infection cleared. ..

Polymerase Chain Reaction:

Article Title: Interpretation of Positive TMA Test Results from PCR-Negative Samples Obtained after Treatment of Chronic Hepatitis C
Article Snippet: .. Subjects with detectable HCV RNA at week 20 by PCR were deemed to be nonresponders to peginterferon/ribavirin and treatment was discontinued at week 24. ..

Article Title: Interpretation of Positive TMA Test Results from PCR-Negative Samples Obtained after Treatment of Chronic Hepatitis C
Article Snippet: .. Consistent with their achieving an SVR, these patients had a prompt drop in HCV RNA on therapy, were repeatedly PCR-negative from week 20 through week 72, and had a significant decline in ALT activity from baseline to week 72. .. Most importantly, all 9 remained HCV RNA-negative by both PCR and TMA after week 72.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    Roche hcv rna quantification
    Mean maximal change from baseline in <t>HCV-RNA</t> per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.
    Hcv Rna Quantification, supplied by Roche, used in various techniques. Bioz Stars score: 89/100, based on 156 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcv rna quantification/product/Roche
    Average 89 stars, based on 156 article reviews
    Price from $9.99 to $1999.99
    hcv rna quantification - by Bioz Stars, 2020-05
    89/100 stars
      Buy from Supplier

    Image Search Results


    Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.

    Journal: PLoS ONE

    Article Title: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

    doi: 10.1371/journal.pone.0204974

    Figure Lengend Snippet: Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.

    Article Snippet: Blood samples for HCV-RNA quantification (using COBAS Ampliprep/COBAS TaqMan HCV Test Version 2.0 [Roche]) and for viral sequencing (using Sanger population sequencing of the HCV NS5B gene) were collected daily while confined and at each follow-up visit.

    Techniques: Infection, Standard Deviation

    Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (

    Journal: PLoS ONE

    Article Title: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

    doi: 10.1371/journal.pone.0204974

    Figure Lengend Snippet: Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (

    Article Snippet: Blood samples for HCV-RNA quantification (using COBAS Ampliprep/COBAS TaqMan HCV Test Version 2.0 [Roche]) and for viral sequencing (using Sanger population sequencing of the HCV NS5B gene) were collected daily while confined and at each follow-up visit.

    Techniques:

    Virological response over time. Virological response is defined as undetectable HCV RNA (Roche COBAS TaqMan ® 2.0 HCV Test). EOT end of treatment, HCV hepatitis C virus; RNA ribonucleic acid

    Journal: Infectious Diseases and Therapy

    Article Title: Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

    doi: 10.1007/s40121-016-0110-5

    Figure Lengend Snippet: Virological response over time. Virological response is defined as undetectable HCV RNA (Roche COBAS TaqMan ® 2.0 HCV Test). EOT end of treatment, HCV hepatitis C virus; RNA ribonucleic acid

    Article Snippet: Outcomes The primary efficacy variable was SVR12 defined as undetectable HCV RNA (Roche COBAS TaqMan 2.0 HCV Test, [lower limit of detection for genotype 1 10–15 IU/mL, lower limit of quantification 25 IU/mL]) after 12 weeks of untreated follow-up (≥70 days after actual end of treatment [EOT]).

    Techniques:

    Patient disposition and reason for premature withdrawal from treatment or follow-up. Asterisk early response is defined as patients with undetectable HCV RNA at week 8, HCV RNA

    Journal: Infectious Diseases and Therapy

    Article Title: Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

    doi: 10.1007/s40121-016-0110-5

    Figure Lengend Snippet: Patient disposition and reason for premature withdrawal from treatment or follow-up. Asterisk early response is defined as patients with undetectable HCV RNA at week 8, HCV RNA

    Article Snippet: Outcomes The primary efficacy variable was SVR12 defined as undetectable HCV RNA (Roche COBAS TaqMan 2.0 HCV Test, [lower limit of detection for genotype 1 10–15 IU/mL, lower limit of quantification 25 IU/mL]) after 12 weeks of untreated follow-up (≥70 days after actual end of treatment [EOT]).

    Techniques:

    Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (

    Journal: PLoS ONE

    Article Title: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

    doi: 10.1371/journal.pone.0204974

    Figure Lengend Snippet: Mean (±SEM) HCV-RNA change from baseline (log 10 IU/mL) over time following multiple oral administrations of AL-335 (tablet form) under fed conditions (Part III, Days 1–7; pharmacodynamic set). Values below the LLOQ (

    Article Snippet: Blood samples for HCV-RNA quantification (using COBAS Ampliprep/COBAS TaqMan HCV Test Version 2.0 [Roche]) and for viral sequencing (using Sanger population sequencing of the HCV NS5B gene) were collected daily while confined and at each follow-up visit.

    Techniques:

    Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.

    Journal: PLoS ONE

    Article Title: Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

    doi: 10.1371/journal.pone.0204974

    Figure Lengend Snippet: Mean maximal change from baseline in HCV-RNA per cohort between Day 1 and Day 10 in Part III. a All randomized subjects in the HCV GT4–6 cohort were infected with GT4. Baseline is defined as the average of Day -2 and Day 1 pre-dose values. comp = compensated, GT = genotype, HCV = hepatitis C virus, RNA = ribonucleic acid, SD = standard deviation.

    Article Snippet: Blood samples for HCV-RNA quantification (using COBAS Ampliprep/COBAS TaqMan HCV Test Version 2.0 [Roche]) and for viral sequencing (using Sanger population sequencing of the HCV NS5B gene) were collected daily while confined and at each follow-up visit.

    Techniques: Infection, Standard Deviation

    Hepatitis C virus (HCV) RNA viral kinetic plots for those who did not achieve sustained virologic response (SVR) 12 (N = 7). HCV RNA (in log 10 IU/mL) is shown on the y -axis and study follow-up visits are shown on the x -axis.

    Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

    Article Title: Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

    doi: 10.1093/cid/cix025

    Figure Lengend Snippet: Hepatitis C virus (HCV) RNA viral kinetic plots for those who did not achieve sustained virologic response (SVR) 12 (N = 7). HCV RNA (in log 10 IU/mL) is shown on the y -axis and study follow-up visits are shown on the x -axis.

    Article Snippet: The primary efficacy endpoint was the rate of SVR, which was defined as HCV RNA undetectable ( < LLOQ TND [target not detected]) (Roche COBAS Taqman HCV Test 2.0 with LLOQ of 15 IU/mL) 12 weeks after date of last dose of study treatment (SVR12).

    Techniques: